Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $6.9 million.

  • Amphastar Pharmaceuticals' Gains from Investment Securities rose 1145.68% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 7058.41%. This contributed to the annual value of $6.7 million for FY2024, which is 1426.22% down from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Gains from Investment Securities stood at $6.9 million, which was up 1145.68% from $6.9 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities ranged from a high of $16.6 million in Q2 2023 and a low of $1.1 million during Q4 2022
  • Over the past 5 years, Amphastar Pharmaceuticals' median Gains from Investment Securities value was $6.5 million (recorded in 2022), while the average stood at $6.6 million.
  • Within the past 5 years, the most significant YoY rise in Amphastar Pharmaceuticals' Gains from Investment Securities was 41456.69% (2021), while the steepest drop was 7489.81% (2021).
  • Over the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $2.6 million in 2021, then tumbled by 56.08% to $1.1 million in 2022, then soared by 368.12% to $5.4 million in 2023, then tumbled by 31.39% to $3.7 million in 2024, then soared by 87.97% to $6.9 million in 2025.
  • Its last three reported values are $6.9 million in Q3 2025, $6.9 million for Q2 2025, and $7.8 million during Q1 2025.